» Articles » PMID: 24576831

Diagnostic Value of Brain Chronic Black Holes on T1-weighted MR Images in Clinically Isolated Syndromes

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2014 Mar 1
PMID 24576831
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-enhancing black holes (neBHs) are more common in multiple sclerosis (MS) patients with longer disease durations and progressive disease subtypes.

Objective: Our aim was to analyse the added value of neBHs in patients with clinically isolated syndromes (CISs) for predicting conversion to clinically definite MS (CDMS).

Methods: Patients were classified based on the presence or absence of neBHs and on the number of Barkhof-Tintoré (B-T) criteria fulfilled. Dissemination in space (DIS) was defined as the presence of at least three of the four B-T criteria. Dissemination in time (DIT)1 was defined by simultaneous presence of enhancing and non-enhancing lesions. DIT2 was defined by simultaneous presence of neBHs and T2 lesions not apparent on T1-weighted images.

Results: Focal T2-hyperintense brain lesions were identified in 87.7% of the 520 CIS patients, and 41.4% of them presented at least one neBH. Patients meeting DIS, DIT1, and DIT2 had a significantly higher rate of conversion to CDMS. After adjusting for DIS, only patients who fulfilled DIT1 preserved a significant increase in CDMS conversion.

Conclusions: Non-enhancing black holes in CIS patients are associated with a higher risk of conversion to CDMS. However, the predictive value of this finding is lost when added to the DIS criteria.

Citing Articles

Predictive MRI Biomarkers in MS-A Critical Review.

Tiu V, Enache I, Panea C, Tiu C, Popescu B Medicina (Kaunas). 2022; 58(3).

PMID: 35334554 PMC: 8949449. DOI: 10.3390/medicina58030377.


Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients.

Nowaczyk N, Kalinowska-Lyszczarz A, Paprzycki W, Michalak S, Kazmierski R, Pawlak M Neurol Neurochir Pol. 2019; 53(1):18-25.

PMID: 30742302 PMC: 8800152. DOI: 10.5603/PJNNS.a2018.0001.


Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson A Nat Rev Neurol. 2018; 14(2):75-93.

PMID: 29326424 DOI: 10.1038/nrneurol.2017.171.


Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.

Puthenparampil M, Federle L, Poggiali D, Miante S, Signori A, Pilotto E PLoS One. 2017; 12(8):e0183957.

PMID: 28850630 PMC: 5574611. DOI: 10.1371/journal.pone.0183957.


MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca M, Ciccarelli O, De Stefano N, Evangelou N, Kappos L Lancet Neurol. 2016; 15(3):292-303.

PMID: 26822746 PMC: 4760851. DOI: 10.1016/S1474-4422(15)00393-2.